Last month marked Women’s History Month, and in February there was International Day of Women and Girls in Science, too. But, ...

Oligonucleotide (oligo) therapies have been in development for decades. Recent advances in molecular design, chemistry, ...

In addition to the three NPVs, the FDA also announced the approval of an IND submission for DemeRx, which is investigating ...

Clinical trial sponsors and contract research organisations (CROs) are expanding clinical trials internationally to access ...

Regeneron has become the first company to get US approval for a gene therapy for congenital hearing loss, after the FDA gave ...

Armed with new phase 3 data, Novo Nordisk has said it will file for approval of oral formulations of its GLP-1 agonist ...

The regulator has sent a complete response letter (CRL) to AbbVie for trenibotulinumtoxinE (TrenibotE), a follow-up to its ...

Last year's $2.5 billion acquisition of Dynavax started to deliver, with a 2.1% rise in vaccine sales to €1.3 billion, driven ...

The Telethon Undiagnosed Diseases Programme (TUDP), run by the Naples-based biomedical charity Fondazione Telethon, has ...

The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu – long considered to be a ...

Berkeley, California biotech Ray Therapeutics, a specialist in the development of optogenetic therapies for eye disorders, ...

The oral BTK inhibitor race in RMS is now a two-horse affair, with fenebrutinib vying against Novartis' remibrutinib, already ...